ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
ViaDerma Announces Intent to Launch a New Minoxidil Hair Regrowth Product
The global hair restoration market is expected to reach $13.6 billion by 2028
到 2028 年，全球頭髮恢復市場預計將達到 13.6 億美元
LOS ANGELES, March 08, 2023 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM) is pleased to announce their plans to launch a new hair regrowth product using Minoxidil (topical route). The company will incorporate their proprietary, patent-pending dual carrier transdermal delivery technology with Minoxidil to create their new hair regrowth product.
洛杉磯，2023 年 3 月 8 日（環球美通社）-維亞德瑪有限公司（OTC 粉紅色：VDRM）欣然宣布，他們計劃使用米諾地爾（主題路線）推出新的頭髮再生產品。該公司將與 Minoxidil 結合其專有的正在申請專利的雙載體透皮遞送技術，以創造新的頭髮再生產品。
ViaDerma's unique transdermal delivery system facilitates the transfer of chemicals through the stratum corneum, the outermost layer of the skin with a diffusion constant that is 10,000x higher than other products on the market. This allows much more of the active ingredient to be absorbed into the skin and work better and faster, often producing significantly better results than traditional topical treatments. Previous testing conducted by ViaDerma has yielded exceptional results at regrowing hair.
ViaDerma 獨特的透皮傳遞系統有助於化學物質通過角質層轉移，皮膚最外層具有擴散常數，比市面上其他產品高出 10,000 倍。這使得更多的活性成分被吸收到皮膚中，並更好，更快地工作，通常比傳統的局部治療產生更好的效果。ViaDerMA 先前進行的測試在再生頭髮方面取得了出色的效果。
A recently published report showed the global Minoxidil market size was valued at USD 1.038 billion in 2022 and is expected to expand at a CAGR of 5.48% during the forecast period, reaching USD 1.43 billion by 2028. The global hair restoration market as a whole which includes surgical and noninvasive treatments is expected to reach USD 13.6 billion by 2028, according to this research report by Grand View Research. Minoxidil is the active ingredient in several top selling hair regrowth products including Rogaine, Rogaine Extra Strength and Lipogaine.
最近發表的一份報告顯示，2022 年全球米諾地爾市場規模為 1.038 億美元，預計在預測期內將以 5.48％ 的複合年增長率增長，到 2028 年達到 1.43 億美元。根據宏觀研究所（Grand View Research）的這份研究報告，到 2028 年，整個包括外科和非侵入性治療在內的全球頭髮修復市場預計將達到 13.6 億美元。米諾地爾是幾種最暢銷的頭髮再生產品中的活性成分，包括 Rogaine，Rogaine 額外強度和硫辛。
ViaDerma's President & CEO, Dr. Chris Otiko said, "We are very excited to announce these plans for our new product and to enter this rapidly expanding industry. Our objective is to create the best hair regrowth product on the market."
ViaDerma 的總裁兼首席執行官 Chris Otiko 博士表示：「我們很高興宣布這些針對我們新產品的計劃，並進入這個快速發展的行業。我們的目標是創造市場上最好的頭髮再生產品。」
FDA registration of the product is expected to be completed within the next 90 days. The company expects to have the new product on the market later this year.
該產品的 FDA 註冊預計將在接下來的 90 天內完成。該公司預計將在今年晚些時候在市場上推出新產品。
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative technology to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, visit:
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management's beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
關於維亞德瑪公司
ViaDerma, Inc.（OTC：VDRM）是一家上市的專業製藥公司，致力於將新產品推向市場，並將其創新技術授權給製藥行業在各種治療領域的當前領導者。如需詳細資訊，請造訪：
任何對未來表現的預測都是證券法下的「前瞻性聲明」。這些聲明包括在內，讓潛在投資者有機會了解管理層對未來的信念和意見，以便他們可以將這些信念和意見作為評估投資的眾多因素中的一個因素。
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter:
Follow ViaDerma on Facebook:
聯絡資訊：
投資者關係
電郵地址:ir@viaderma.com
電話：
在推特上關注維亞德瑪：
在臉書上關注維亞德瑪：